Soon it won’t be possible to fund the huge enterprises of the leading pharma companies with a handful of blockbuster drugs. The only question is whether they can change and innovate in time.
The days of medical charities passively handing out grants and waiting to hear of any results are over. Now the money comes attached to sophisticated, target-driven deals.
RDP Associates, a Canadian tax consultancy with 20 years’ experience in advising companies on how to maximise their R&D tax credits, is bringing its services to Europe.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.